Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial

Stock Information for Hemostemix

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Hemostemix

Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Hemostemix Grants Stock Options
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.